From ‘Not Considering’ to ‘Inevitable Path’: Ai Er Ophthalmology Files for Hong Kong IPO

Ai Er Ophthalmology, the leading domestic private ophthalmology enterprise in China, has officially disclosed its prospectus for a Hong Kong IPO after experiencing a decline in net profit and tax payment controversies. The prospectus reveals that the funds raised through this IPO will be mainly allocated to three core areas: upgrading mainland medical institution construction, domestic and international ophthalmology institution mergers and integration, and the development of ophthalmology artificial intelligence and technology ecosystem. Notably, less than a year ago at the 2024 shareholders’ meeting, Ai Er Ophthalmology’s Chairman, Chen Bang, explicitly stated “not considering an H-share listing.” Explaining the strategic…